Many of these gene flaws - there are plenty of them, with names like BCR-ABL - are relative newcomers to medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
a- medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
b- medical terminology like a majority of the new anti-tumor drugs that are still in early testing, and aimed at them.
c- medical terminology, as are a majority of the new anti-tumor drugs that are still in early testing, aimed at them.
d- medical terminology like a majority of the new anti-tumor drugs, still in early testing, that are aimed at them.
e- medical terminology, as are a majority of the new anti-tumor drugs, still in early testing, and aimed at them.
Please help me understand how answer A is correct? and why is d incorrect.
This is a Veritas question and I dont have access to post/ask in their forum so I am asking here.